Akebia Therapeutics, Inc. 8-K Filing
Ticker: AKBA · Form: 8-K · Filed: Nov 17, 2025 · CIK: 1517022
| Field | Detail |
|---|---|
| Company | Akebia Therapeutics, Inc. (AKBA) |
| Form Type | 8-K |
| Filed Date | Nov 17, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Akebia Therapeutics, Inc. (ticker: AKBA) to the SEC on Nov 17, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.00001 (ich registered Common Stock, par value $0.00001 per share AKBA The Nasdaq Capital Marke).
How long is this filing?
Akebia Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 567 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 567 words · 2 min read · ~2 pages · Grade level 12.6 · Accepted 2025-11-17 07:54:06
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share AKBA The Nasdaq Capital Marke
Filing Documents
- akba-20251112.htm (8-K) — 29KB
- 0001517022-25-000048.txt ( ) — 156KB
- akba-20251112.xsd (EX-101.SCH) — 2KB
- akba-20251112_def.xml (EX-101.DEF) — 4KB
- akba-20251112_lab.xml (EX-101.LAB) — 24KB
- akba-20251112_pre.xml (EX-101.PRE) — 14KB
- akba-20251112_htm.xml (XML) — 3KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed, on May 24, 2023, Akebia Therapeutics, Inc. (the "Company") and MEDICE Arzneimittel Putter GmbH & Co. KG ("Medice") entered into a License Agreement (the "License Agreement") pursuant to which the Company granted to Medice an exclusive license to develop and commercialize Vafseo for the treatment of anemia in patients with chronic kidney disease in Europe and certain other countries. On November 12, 2025, the Company and Medice entered into Amendment #1 to License Agreement (the "Amendment"). Pursuant to the Amendment, the Company agreed to supply vadadustat drug substance ("Drug Substance") to Medice pursuant to the terms of a supply agreement dated concurrently with the Amendment and granted Medice the right to manufacture Vafseo tablets using the Drug Substance to be supplied by the Company. In addition, the Amendment provides that any know-how or patent rights arising out of Medice's manufacture of Vafseo tablets will be owned by the Company. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which the Company expects to file as an exhibit to its Annual Report on Form 10-K for the year ended December 31, 2025. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AKEBIA THERAPEUTICS, INC. Date: November 17, 2025 By: /s/ John P. Butler Name: John P. Butler Title: President and Chief Executive Officer